Top

Published in:

01-06-2017 | Original Article

Comparison of the tolerability of newly introduced childhood vaccines in the Netherlands

Authors: Jeanet M. Kemmeren, Nicoline AT van der Maas, Hester E. de Melker

Published in: European Journal of Pediatrics | Issue 6/2017

Abstract

In 2011, the 7-valent conjugated pneumococcal vaccine (PCV7) was replaced by the 10-valent vaccine (PCV10) and universal hepatitis B vaccination has been introduced in the Netherlands. A questionnaire study was conducted to assess the tolerability of DTaP-IPV-Hib + PCV7 (PCV7-cohort), DTaP-IPV-Hib + PCV10 (PCV10-cohort), and DTaP-IPV-Hib-HepB + PCV10 (HepB-cohort). Parents were asked to report in questionnaires local reactions and systemic adverse events (AEs) before and after vaccination of their infant at 2, 3, 4, and 11 months of age. For 29.0 and 29.4% infants of the PCV7-cohort, at least one local reaction was reported in the week after the first dose of DTaP-IPV (left leg) and PCV-7 vaccination (right leg). Significantly more infants from the PCV10-cohort (45.1%, p < 0.001 and 44.6%, p < 0.001) and HepB-cohort (42.6%, p < 0.001 and 41.9%, p < 0.001) reported at least one local reaction. This effect was less pronounced after the successive doses. Most of the infants experienced at least one systemic AE, and after dose 4, this was higher for infants in the PCV10-cohort (65.9%, p = 0.047) and HepB-cohort (70.6%, p = 0.000) compared to the PCV7-cohort (62.3%).

Conclusion: Addition of antigens to a vaccine resulted in a higher reactogenicity, but the AEs were in general mild and transient.

What is Known:

• Assessment of adverse events is crucial for achieving the highest safety in immunization programs, in order to inform public health actions and maintain public confidence in immunization programs.

What is New:

• Newly introduced vaccines DTaP-IPV-Hib-HepB and PCV10 are generally safe and well tolerated in infants.

• These results are useful for information purposes and for monitoring variations in rates of AEs in the general population or in the target group over time.

Omer SB, Salmon DA, Orenstein WA, deHart MP, Halsey N (2009) Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med 360:1981–1988CrossRefPubMed

Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Vadheim CM, Marcy SM, Ward JI, Wise RP, Wassilak SG, Hadler SC (1997) Vaccine safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team Pediatrics 99:765–773PubMed

Tozzi AE, Asturias EJ, Balakrishnan MR, Halsey NA, Law B, Zuber PL (2013) Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine 31:5041–5046CrossRefPubMed

Aristegui J, Dal-Re R, Diez-Delgado J, Mares J, Casanovas JM, Garcia-Corbeira P, De Frutos E, Van Esso D, Verdaguer J, De la Flor J, Moraga F, Boceta R, Garcia-Martinez JA (2003) Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine 21:3593–3600CrossRefPubMed

van den Bergh MR, Spijkerman J, Francois N, Swinnen K, Borys D, Schuerman L, Veenhoven RH, Sanders EA (2016) Immunogenicity, safety and reactogenicity of a booster dose of the 10-valent pneumococcal nontypeable H. influenzae protein D conjugate vaccine coadministered with DTPa-IPV-Hib in Dutch children: a randomized controlled trial. Pediatr Infect Dis J 35:e206–e219CrossRefPubMed

Bar-On ES, Goldberg E, Fraser A, Vidal L, Hellmann S, Leibovici L (2009) Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Cochrane database Syst rev:CD005530

Davis RL, Marcuse E, Black S, Shinefield H, Givens B, Schwalbe B et al (1997) MMR2 immunisation at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunisation in the vaccine safety Datalink project. Pediatrics 100:767–771CrossRefPubMed

Marcy SM, Kohl KS, Dagan R, Nalin D, Blum M, Jones MC, Hansen J, Labadie J, Lee L, Martin BL, O’Brien K, Rothstein E, Vermeer P, Brighton Collaboration Fever Working G (2004) Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 22:551–556CrossRefPubMed

Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R (2006) The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 25:507–512CrossRefPubMed

10.

Luman ET, Barker LE, McCauley MM, Drews-Botsch C (2005) Timeliness of childhood immunizations: a state-specific analysis. Am J Public Health 95:1367–1374CrossRefPubMedPubMedCentral

11.

Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, Russell A (2007) Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J 26:496–500CrossRefPubMed

12.

Dodd D (2003) Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care 9:S6–12PubMed

13.

Prymula R, Bergsaker MR, Esposito S, Gothefors L, Man S, Snegova N, Stefkovicova M, Usonis V, Wysocki J, Douha M, Vassilev V, Nicholson O, Innis BL, Willems P (2014) Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet 383:1313–1324CrossRefPubMed

14.

Kilpi TM, Silfverdal SA, Nilsson L, Syrjanen R, Belloni C, Desole M, Triban C, Storsaeter J, Soila M, Jacquet JM (2009) Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11–12 months of age. Hum Vaccin 5:18–25CrossRefPubMed

15.

Plosker GL (2014) 10-valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children. Paediatric drugs 16:425–444CrossRefPubMed

16.

Ruiz-Palacios GM, Guerrero ML, Hernandez-Delgado L, Lavalle-Villalobos A, Casas-Munoz A, Cervantes-Apolinar Y, Moreira M, Schuerman L (2011) Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants. Hum Vaccin 7:1137–1145CrossRefPubMed

17.

Shao PL, Lu CY, Hsieh YC, Taiwan Infanrix-049 Study G, Bock HL, Huang LM (2011) Immunogenicity and reactogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type B. Journal of the Formosan Medical Association = Taiwan yi zhi 110:336–341CrossRefPubMed

18.

Tichmann-Schumann I, Soemantri P, Behre U, Disselhoff J, Mahler H, Maechler G, Sanger R, Jacquet JM, Schuerman L (2005) Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 24:70–77CrossRefPubMed

19.

Tozzi AE, Azzari C, Bartolozzi G, Esposito S, Fara GM, Giudice ML (2007) Can hexavalent vaccines be simultaneously administered with pneumococcal or meningococcal conjugate vaccines? Hum Vaccin 3:252–259CrossRefPubMed

20.

van den Bergh MR, Spijkerman J, Francois N, Swinnen K, Borys D, Schuerman L, Veenhoven RH, Sanders EA (2011) Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial. Pediatr Infect Dis J 30:e170–e178CrossRefPubMed

21.

Zepp F, Knuf M, Heininger U, Jahn K, Collard A, Habermehl P, Schuerman L, Sanger R (2004) Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 22:2226–2233CrossRefPubMed

22.

Diaz-Mitoma F, Halperin SA, Tapiero B, Hoffenbach A, Zappacosta PS, Radley D, Bradshaw S, Martin JC, Boslego JW, Hesley TM, Bhuyan PK, Silber JL (2011) Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age. Vaccine 29:1324–1331CrossRefPubMed

23.

Halperin SA, Tapiero B, Diaz-Mitoma F, Law BJ, Hoffenbach A, Zappacosta PS, Radley D, McCarson BJ, Martin JC, Brackett LE, Boslego JW, Hesley TM, Bhuyan PK, Silber JL (2009) Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12–14 months of age. Vaccine 27:2540–2547CrossRefPubMed

24.

Schmitt HJ, Knuf M, Ortiz E, Sanger R, Uwamwezi MC, Kaufhold A (2000) Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr 137:304–312CrossRefPubMed

25.

Edelman K, Malmstrom K, He Q, Savolainen J, Terho EO, Mertsola J (1999) Local reactions and IgE antibodies to pertussis toxin after acellular diphtheria-tetanus-pertussis immunization. Eur J Pediatr 158:989–994CrossRefPubMed

26.

White OJ, Rowe J, Richmond P, Marshall H, McIntyre P, Wood N, Holt PG (2010) Th2-polarisation of cellular immune memory to neonatal pertussis vaccination. Vaccine 28:2648–2652CrossRefPubMed

27.

Vesikari T, Forsten A, Desole MG, Ferrera G, Caubet M, Mesaros N, Boutriau D (2013) A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study. Pediatr Infect Dis J 32:521–529CrossRefPubMed

28.

Siegrist CA (2007) Mechanisms underlying adverse reactions to vaccines. J Comp Pathol 137(Suppl 1):S46–S50CrossRefPubMed

29.

Rothman KJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1:43–46CrossRefPubMed

30.

De Serres G, Duval B, Boulianne N, Rochette M, Dionne M, Fradet MD, Masse R (2001) Importance of attributable risk in monitoring adverse events after immunization: hepatitis B vaccination in children. Am J Public Health 91:313–315CrossRefPubMedPubMedCentral

Title: Comparison of the tolerability of newly introduced childhood vaccines in the Netherlands
Authors: Jeanet M. Kemmeren
Nicoline AT van der Maas
Hester E. de Melker
Publication date: 01-06-2017
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Pediatrics / Issue 6/2017
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-017-2901-4

At a glance: The STEP trials

Springer Medicine

Comparison of the tolerability of newly introduced childhood vaccines in the Netherlands

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2017

Ebola virus disease in children during the 2014–2015 epidemic in Guinea: a nationwide cohort study

Vitamin D in European children—statement from the European Academy of Paediatrics (EAP)

A comparison of McGrath MAC® and standard direct laryngoscopy in simulated immobilized cervical spine pediatric intubation: a manikin study

Transanal irrigation is effective in functional fecal incontinence

A three-step diagnosis of pediatric pneumonia at the emergency department using clinical predictors, C-reactive protein, and pneumococcal PCR

Health, integrity, and doping in sports for children and young adults. A resolution of the European Academy of Paediatrics